CA-AMAZENTIS
Pioneering life sciences company, Amazentis , today announces new clinical findings and the commercial launch of Timeline Cellular Nutrition in the United States. After a decade of research by leading scientists and medical doctors, Timeline Nutrition is the first brand to offer Mitopure™, a highly pure form of Urolithin A proven to help counter age-associated cellular decline and improve muscular strength.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200727005447/en/
- A randomized, double-blind, placebo-controlled clinical trial (NCT03464500 ) in healthy middle-aged participants (40 to 65 years old) showed that 4 months of daily consumption of 500mg Mitopure™ (highly pure Urolithin A) led to a significant improvement in leg muscle strength.
- A separate randomized clinical trial (NCT04160312 ) conducted in healthy adults (18-80 years old) in the USA compared Urolithin A levels following consumption of Mitopure™ and pomegranate juice. It showed that 500mg of Mitopure™ delivers greater than 6X more Urolithin A compared to 8oz (240ml) of 100% pomegranate juice.
- Amazentis is launching the first product containing clinically proven Mitopure™ exclusively direct-to-consumer through the Timeline Nutrition website.
Many people begin to experience a loss in muscle strength starting in their 40s due to age-associated declines in cellular bioenergetics and mitochondrial function. Timeline is formulated with Mitopure™, a proprietary ingredient and highly pure form of Urolithin A. This bioactive is produced by the gut microbiome in only a limited portion of the population. Mitopure™ is the only compound shown to increase muscle function by activating the selective recycling of damaged mitochondria (the powerhouse of the cell) via an essential anti-aging process known as mitophagy.
“For the first time we have now shown that consuming Mitopure™ on a regular basis for 4 months triggers meaningful physiological changes in the body and significantly improves leg muscle strength” says Amazentis Chairman & Co-Founder, Patrick Aebischer, MD “this is a breakthrough in the translation of science-backed nutrition targeting muscle and healthy aging.”
Timeline is particularly effective because precisely calibrated doses of Mitopure™ deliver Urolithin A directly and activate mitophagy within the body—regardless of your diet or microbiome. This new clinical data showed that only 12% of participants had detectable levels of Urolithin A entering the study. Overall, participants showed a greater than 6-fold improvement in Urolithin A levels over 24 hours after consuming 500mg of Mitopure™ when compared to 8oz (240mL) of 100% pomegranate juice.
“At Amazentis, we’re dedicated to developing the next generation of nutrition products targeting cellular health and mitochondrial function. Now, more than ever, consumers appreciate the importance of staying healthy and maintaining muscle function. Timeline Nutrition brings together cutting-edge science with a great tasting product,” says Amazentis CEO and Co-Founder, Chris Rinsch, PhD.
Timeline’s first product comes in the form of a delicious Berry & Pomegranate flavored powder that can be mixed in with your daily smoothie, yogurt, and other breakfast favorites. Timeline is exclusively available for purchase online for consumers in the United States starting at $3.33 per day for a four-month supply. Visit www.timelinenutrition.com for more information.
* 500mg of Mitopure™ have been shown to (1) induce gene expression related to mitochondrial function and metabolism and (2) increase the strength of the hamstring leg muscle in measures of knee extension and flexion in overweight 40 to 65 year olds. Data from two randomized double-blind placebo-controlled human clinical trials.
About Timeline
Timeline Nutrition is the first brand to offer Mitopure™, a highly pure form of Urolithin A. This novel nutrition brand was developed by Amazentis on the belief that uncompromising research can unlock a new class of nutrition that is backed by cutting edge science. As scientists, we know that physical decline from aging can’t be stopped. However, through its groundbreaking research, Timeline is committed to developing products designed to help reduce the impact of time on health. For more information, please visit www.timelinenutrition.com
.
About Mitopure™
Mitopure™ is a highly pure form of Urolithin A; a bioactive dietary metabolite that is produced by gut bacteria after eating certain foods, such as the pomegranate, though it is difficult for most people to get enough of this specialized nutrient from food alone. Mitopure™ has been shown to improve mitochondrial function by stimulating mitophagy, a process by which aging and damaged mitochondria are cleared from the cell, making way for healthy mitochondria to grow. Mitopure™ has been favorably reviewed by the U.S. Food and Drug Administration (FDA) and deemed safe following a GRAS (generally recognized as safe) filing. Mitopure™ has been extensively evaluated pre-clinically and clinically to support its use in humans for nutritional supplementation. For more information, please visit www.mitopure.com
.
About Amazentis
Amazentis is an innovative life sciences company employing today’s leading research and clinical science to develop the next generation of products targeting mitochondrial health for advanced nutrition. Amazentis has previously published its research on Mitopure™ Urolithin A in top peer reviewed scientific journals such as Nature Medicine
(doi:10.1038/nm.4132) and Nature Metabolism
(doi: 10.1038/s42255-019-0073-4). The company has a global strategic partnership with Nestlé Health Science to expand the health applications of Mitopure™ linked to mitochondrial and cellular decline. For more information on Amazentis, please visit www.amazentis.com
.
Related Links
https://www.timelinenutrition.com
https://www.mitopure.com
https://www.amazentis.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20200727005447/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Access Advance Welcomes Xiaomi to HEVC Advance and VVC Advance Patent Pools as a Licensor and Licensee18.11.2025 02:00:00 CET | Press release
Access Advance LLC, an independent licensing administrator for leading video codec patent pools, today announced that Xiaomi has joined the HEVC Advance Patent Pool and the VVC Advance Patent Pool, as a Licensor and Licensee. "We are delighted to welcome Xiaomi to the Access Advance licensing community," said Peter Moller, CEO of Access Advance. "Xiaomi's participation in both our HEVC and VVC patent pools represents a significant milestone in the video codec licensing landscape. Their joining of the HEVC Advance Patent Pool, which provides them with access to tens of thousands of essential patents for the widely adopted H.265 standard, and their dual role as both a licensor and licensee in the VVC Advance Patent Pool, demonstrates their commitment to innovation and the recognition of the value of patent pools that balance the interest of patent owners and implementers. In addition, it highlights their support for Access Advance’s efforts to bring a one-pool solution to video codec lic
Venture Global Files FERC Application for Plaquemines Expansion Project18.11.2025 00:02:00 CET | Press release
Today, Venture Global, Inc. (NYSE: VG) filed with the Federal Energy Regulatory Commission (FERC) its application for the permitting and approval of the Plaquemines LNG brownfield expansion project. In addition, Venture Global has filed with the U.S. Department of Energy (DOE) for the export authorizations associated with this expansion. The Plaquemines Expansion was announced earlier this year with U.S. Secretary of Energy Chris Wright, U.S. Secretary of the Interior Doug Burgum, and Louisiana Governor Jeff Landry. Venture Global has since increased the expected output from this project by nearly 40% from the previously announced plans due to the continued optimization of our liquefaction trains and strong market demand. This bolt-on expansion will be built incrementally in three phases and consist of 32 modular liquefaction trains, adding in total over 30.0MTPA in peak production capacity. This will bring the total peak production capacity across the entire Plaquemines complex to ove
Global EV Alliance Releases EV Driver Survey Results: Myths Are Slowing EV Market17.11.2025 19:19:00 CET | Press release
In a groundbreaking survey of more than 26,000 EV drivers across 30 countries, an overwhelming 77% say persistent myths about electric cars are the single biggest obstacle to EV adoption in their nations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251118388193/en/ There are still significant differences in the EV market across countries, and not everyone has a wide range of car brands to choose from. Photo: Markus Rotevatn/Norwegian EV Association. 83% say they believe policy measures are needed to increase EV sales in their country. “Misinformation about EVs is a serious challenge. It can make policymakers less confident that electric vehicles are a viable solution to climate change and local air pollution,” says Joel Levin, chair of GEVA and Director of Plug in America. One common myth in many countries is that electric cars are a fire hazard. 88% of the EV drivers in the survey say they aren’t worried about their EV b
Dilawer Farazi Returns to Loomis Sayles as Co-Head and Portfolio Manager on the Emerging Markets Debt Team17.11.2025 16:59:00 CET | Press release
Loomis, Sayles & Company is pleased to announce that Dilawer Farazi, ACA, has rejoined the firm as Co-Head and Portfolio Manager of the Emerging Markets Debt (EMD) Team. Dilawer becomes the firm’s first London-based portfolio manager. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251117681347/en/ Dilawer Farazi, ACA, has rejoined Loomis Sayles as Co-Head and Portfolio Manager of the Emerging Markets Debt Team Dilawer brings over two decades of experience in emerging markets credit, having previously served as a Senior Credit Research Analyst at Loomis Sayles from 2018 to 2020. He rejoins the firm from Royal London Asset Management (RLAM), where he led the Emerging Markets Credit team and managed approximately USD $1 billion in assets across EM credit. At RLAM, he launched the firm’s first dedicated emerging markets funds, including an emerging markets corporate bond fund and an emerging markets short duration credit fund. I
Duravant Announces Retirement of CEO Mike Kachmer, Names Jill Evanko Successor17.11.2025 16:13:00 CET | Press release
Mike Kachmer to retire following a distinguished 43-year career, including nearly 12 years as Chairman & CEO of Duravant Jill Evanko to succeed Mr. Kachmer as Duravant’s Chief Executive Officer Duravant LLC (“Duravant”), a global leader in advanced automation solutions, announced today that Mike Kachmer will retire from his role as Chief Executive Officer after a highly successful tenure with the company. Duravant’s Board of Directors has named Jill Evanko as CEO, joining the company on January 5, 2026. To ensure a seamless transition, Mr. Kachmer will continue to serve as Chairman of Duravant. Mr. Kachmer will also continue to serve on the Board of Directors for Northwestern Memorial Healthcare and The London Clinic. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251117036720/en/ Mike Kachmer “It has been a true honor and a humbling experience to lead this incredible company,” said Mr. Kachmer. “I am profoundly grateful to
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom